

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D.  
Serial No.: **10/585,609**  
Filed: July 10, 2006  
Title: USE OF SUBSTITUTED 2-AMINOTETRALINS FOR PREVENTIVE  
TREATMENT OF PARKINSON'S DISEASE  
Group Art Unit: 1614  
Examiner: D. Stemmer  
Confirmation No.: 7974  
Docket No.: **6102-000013/US/NP**  
Client Ref.: P/Sche/V/9/03

**SUBMITTED ELECTRONICALLY VIA EFS-WEB**

January 24, 2008

Commissioner for Patents  
Office of PCT Legal Administration  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TO THE ATTENTION OF OFFICE OF PCT LEGAL ADMINISTRATION**

Sir:

RENEWED PETITION UNDER 37 C.F.R. §1.497(d)

(INCLUDING PETITION FOR EXTENSION OF TIME UNDER 37 C.F.R. §1.136(a))

This paper is responsive to the Office communication mailed on August 8, 2007 in which Applicant's petition to correct inventorship in the above-referenced application was dismissed. A two months period for response was set in the communication of August 8, 2007. Applicant hereby makes petition for extension of time of four (4) months to respond. Authorization is provided herewith to charge the fee due under 37 C.F.R. §1.17(a)(4) to Deposit Account No. 08-0750. No additional fee is believed payable in connection herewith; however, if any additional fee should be found necessary, please charge such fee to Deposit Account No. 08-0750.


Dismissal of Applicant's petition to correct inventorship was without prejudice and for

Serial No. 10/585,609  
6102-000013/US/NP  
Renewed petition under 37 C.F.R. §1.497(d)  
January 24, 2008

the reason that written consent of assignee was not provided. Now attached hereto is the Consent of Assignee under 37 C.F.R. §1.497(d).

Applicant believes all conditions for grant of the petition to correct inventorship have now been satisfied. A favorable decision is requested.

Respectfully submitted,  
HARNESS, DICKEY & PIERCE, P.L.C.

A handwritten signature in cursive script that reads "James C. Forbes". The signature is written in dark ink and is positioned above the printed name and title.

James C. Forbes  
Agent for Applicant  
Reg. No. 39,457  
Tel. 847-412-6350

Attachment:  
Consent of Assignee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D., *et al.*  
Serial No.: 10/585,609  
Filed: July 10, 2006  
Title: USE OF SUBSTITUTED 2-AMINOTETRALINS FOR PREVENTIVE  
TREATMENT OF PARKINSON'S DISEASE  
Group Art Unit: 1616  
Examiner: Stemmer, D.  
Confirmation No.: 7964  
Docket No.: 6102-000013/US/NP  
Client Ref.: P/Sche/V/9/03

<b>SUBMITTED ELECTRONICALLY VIA EFS-WEB</b>
---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CONSENT OF THE ASSIGNEE**  
**UNDER 37 C.F.R. §1.497(d)(3)**

Sir:

Schwarz Pharma AG, is the owner by assignment of the entire right, title, and interest of the above referenced patent application. Documentary evidence establishing chain of title from the original owner to the assignee, per 37 C.F.R. § 3.73(b), is recorded in the assignment records of the Patent and Trademark Office with a Recordation Date of March 12, 2007 on Reel 018994 and Frame 0545, as evidenced by attached Notice of Recordation of Assignment Document.

The assignee, Schwarz Pharma AG, hereby consents to correction of inventorship in the above referenced application by deletion of the name of Frank Dressen and retention of Dieter Scheller as sole inventor.

Consent of the Assignee  
Under 37 C.F.R. §1.49(d)(3)  
Serial No. 10/585,609  
6102-000013/US/NP  
Page 2 of 2

The undersigned, whose title is supplied below, is empowered to sign this letter of consent on behalf of the assignee.

Dated: Jan 24, 2008

By: 

Title: Dr. S. Krohn

Associate General Patent Counsel